Citigroup Lowers Accendra Health (NYSE:ACH) Price Target to $4.50

Accendra Health (NYSE:ACH) had its target price dropped by research analysts at Citigroup from $5.00 to $4.50 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s target price points to a potential upside of 43.77% from the stock’s current price.

Several other equities analysts have also recently commented on the company. UBS Group boosted their target price on Accendra Health from $3.00 to $4.50 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Robert W. Baird lifted their price target on Accendra Health from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Tuesday, May 12th. Weiss Ratings raised Accendra Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Finally, Zacks Research upgraded shares of Accendra Health from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $5.00.

Accendra Health Stock Performance

NYSE:ACH opened at $3.13 on Friday. The business’s 50-day simple moving average is $3.12. The company has a market capitalization of $239.70 million, a price-to-earnings ratio of -0.22, a price-to-earnings-growth ratio of 4.84 and a beta of 1.58. Accendra Health has a 52 week low of $1.84 and a 52 week high of $7.99.

Accendra Health (NYSE:ACH) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. Accendra Health had a negative net margin of 39.84% and a negative return on equity of 13.18%. The firm had revenue of $627.78 million for the quarter. As a group, analysts anticipate that Accendra Health will post 0.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Walleye Capital LLC purchased a new stake in Accendra Health during the 1st quarter valued at $27,000. Hsbc Holdings PLC purchased a new stake in shares of Accendra Health during the first quarter worth about $34,000. Abel Hall LLC bought a new stake in shares of Accendra Health in the first quarter worth about $44,000. Keybank National Association OH purchased a new position in Accendra Health during the 1st quarter valued at about $46,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Accendra Health during the 1st quarter valued at about $50,000.

Accendra Health Company Profile

Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services.